
    
      This is a Bayesian adaptive phase 2b, multi-center, double-blind, randomized,
      placebo-controlled, 52-week, dose-ranging study in subjects with active SLE and inadequate
      response to SOC therapies including oral corticosteroids (OCS), immunosuppressants and
      immunomodulators. Previous biologic use is allowed with an adequate washout period.
    
  